NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the
discovery, development and commercialization of novel therapies for the treatment of cancer, visited the Nasdaq MarketSite in Times
Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Athenex aims to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. Athenex has
generated its clinical product candidates through its Orascovery and Src Kinase Inhibition research platforms, which are based on
the Company’s understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively.
“We are pleased to have successfully completed our Initial Public Offering on Nasdaq, an exciting milestone in our Company’s
growth. We remain focused on developing and commercializing safe and efficacious oncology focused medication and continuing to
advance our pipeline candidates through clinical trials,” said Johnson Y.N. Lau, Chief Executive Officer and Board Chairman,
Athenex.
“Nasdaq continues to be the listing venue of choice for innovators in both healthcare and technology, two of the fastest
changing industries. We welcome Athenex and look forward to supporting the company as it advances novel therapies for cancer
treatment and improving health outcomes,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein
should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information
about the company is provided by the company or comes from the company’s public filings and is not independently verified by
Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation
about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future
performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future
results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A
SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and
public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their
business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11.0
trillion. To learn more, visit: http://business.nasdaq.com.
- NDAQG -
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 Stephanie.Lowenthal@nasdaq.com Emily Pan (646) 441-5120 emily.pan@nasdaq.com
